The Press Release
Gosselies and La Louvière, Belgium. The Mutualité Libérale Namur-Hainaut announces funding for the OncoDNA Company’s genetic profiling test. This initiative is a first in Belgium and a major step towards precision medicine.
Decrypting the features of a patient’s tumour provides fresh insight into treatment. Through thorough tumour analysis (DNA, RNA and proteins), oncologists can offer their patients with metastatic cancers suitable treatments, some of which are still in the clinical trial phase. Goal: To fight cancer through customised treatment
Philippe Jacquemin, Director of Mutualité Libérale Hainaut-Namur:
“Each day brings progress in medicine, and we want to support member access to innovations in the field of diagnostics; innovations that have proven successful and equip oncologists with decision-making tools when it comes to treatment. Each cancer has its own set of characteristics and, more importantly, each patient is unique.”
OncoDNA provides comprehensive tests for all of the clinically-relevant cancer biomarkers (DNA profiles, RNA and proteins). Through the analysis of 313 genes or gene regions, in addition to proteins, OncoDNA provides oncologists with a full, detailed report on the features of the patient’s tumour based on which treatment suggestions and potential clinical trials are proposed; whether it involves immunotherapy, targeted treatments or chemotherapy. OncoDNA’s analyses are one of a kind, as they go beyond routine analyses performed in hospitals and can even combine solid biopsy analysis with blood biopsy analysis (circulating tumour DNA).
There is a cost associated with this type of analysis and, currently, these molecular diagnostic tests are not eligible for reimbursement by the INAMI (Institut National d’Assurance Maladie-invalidité [National Institute for Health and Disability Insurance]). Each adult Mutualité Libérale Hainaut-Namur member who has a stage 3 or 4 solid tumour cancer and relapses after first-line treatment will receive a partial reimbursement for their tumour analysis known as “OncoDEEP”, amounting to €1,500, or around half of its cost.
OncoDNA CEO Jean-Pol Detiffe stated:
“We are delighted with Liberal Mutuality initiative and especially pleased that Belgian patients can receive the most suitable treatment for their cancer upon failure of initial treatment. After UK insurers and Luxembourg authorities, this unique tool is, at last, available to Belgian oncologists for use on some of their patients, which not only confirms an increasing interest in our solutions, but also the customisation of cancer treatments. Indeed, in the fight against advanced stage cancer, timing and the right information for making a treatment choice are a must for the patient. With these tests as well as its decision-making algorithms, OncoDNA has demonstrated the unique value provided to the oncologist.”
For any questions, OncoDNA’s scientific staff may be reached at the address email@example.com.
About Mutualité Libérale Hainaut-Namur :
The Mutualité Libérale Hainaut-Namur is active in East Hainaut and the Province of Namur and is affiliated to the National Union of Liberal Mutualities.
It offers many advantages as part of its complementary insurance package as well as its hospitalization and dental insurance organized by the Mutualist Insurance Society HOPITAL PLUS.
Hainaut-Namur Mutuality affiliates also benefit from services organized by the care coordination and independent home-service center COSEDI Hainaut-Namur (coordination of care and home care, support to persons with reduced mobility by volunteers, loan and sale of medical equipment, sale of incontinence equipment).
For more information please visit www.ml.be
About OncoDNA :
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ that continuously ‘learns’ from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to an individual patient’s cancer profile. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, and employs c. 55 employees in four countries. For more information please visit www.oncodna.com
|OncoDNA||+32 (0) 71 18 35 00|
|Jean-Pol Detiffe, CEO|
Mutualité Libérale Hainaut-Namur
+32 (0) 64 27 52 08
Philippe Jacquemin, Director